SINOPHARM [01099] disclosed its monthly return for equity securities for the period ended 28 February 2026. The updated figures show that authorized share capital reached 3.12 billion shares (RMB 1 par value). No changes in authorized or registered share capital were recorded during the month.

Regarding H shares listed on The Stock Exchange of Hong Kong, the number of issued shares remained at 1.34 billion, while the balance for domestic shares not listed stood at 1.78 billion. There were no treasury shares, cancellations, or new issuances during the reporting period. Additionally, sufficiency of the public float requirement for H shares was confirmed.

No other movements, such as share options, warrants, convertibles, or agreements to issue shares, were reported. The announcement was submitted by the company secretary on 5 March 2026.